Evaluation of Dose-Adjusted EPOCH-R Compared with R-CHOP for the Treatment of High-Risk, Aggressive B-Cell Lymphomas: A Single-Center Experience

被引：1
|
作者：
Rockwell, Sarah J.
Richter, Katherine A.
Caddell, Ryan J.
Chavez, Julio C.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-140085
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Pola-R-CHP, R-CHOEP, or R-CHOP in younger patients with high-risk aggressive B-cell lymphoma
    Schmitz, N.
    Tilly, H.
    Ziepert, M.
    Altmann, B.
    Craine, V.
    Yan, M.
    Herbaux, C.
    Frontzek, F.
    Nickelsen, M.
    Hirata, J.
    Sahin, D.
    Lee, C.
    Morschhauser, F.
    Lenz, G.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 209 - 210
  • [32] DA.R-EPOCH Vs. R-CHOP for High-Risk Diffuse Large B-Cell Lymphoma: The Mayo Clinic Florida Experience
    Dholaria, Bhagirathbhai
    Vishnu, Prakash
    Roy, Vivek
    Tun, Han W.
    Sher, Taimur
    Rivera, Candido E.
    Ailawadhi, Sikander
    Diehl, Nancy
    Hodge, David O.
    Moreno-Vanegas, Yenni Alejandro
    BLOOD, 2017, 130
  • [33] Treatment of high risk aggressive B cell lymphomas with DA EPOCH R- the Austrian experience
    Panny, M.
    Prochazka, K.
    Neumeister, P.
    Noesslinger, T.
    Rathkolb, V.
    Holzer, K.
    Boehm, A.
    Keil, F.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 46 - 46
  • [34] Dose-adjusted EPOCH-R therapy in MYC-rearranged diffuse large B-cell lymphoma: not yet the standard of care
    Casan, Joshua M. L.
    Barraclough, Alison
    Shortt, Jake
    Hawkes, Eliza A.
    LANCET HAEMATOLOGY, 2019, 6 (03): : E119 - E119
  • [35] High-grade B-cell lymphoma, not otherwise specified, presenting as primary peritoneal lymphomatosis and successfully treated with dose-adjusted EPOCH-R
    Fujimi, Akihito
    Nagamachi, Yasuhiro
    Yamauchi, Naofumi
    Onoyama, Naoki
    Hayasaka, Naotaka
    Matsuno, Teppei
    Koike, Kazuhiko
    Goto, Yoshiro
    Ihara, Kohji
    Kato, Junji
    Nishisato, Takuji
    Kawase, Hiroshi
    Yano, Tomoyuki
    Kanaseki, Takayuki
    Sugita, Shintaro
    Kobune, Masayoshi
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2024, 64 (01) : 37 - 44
  • [36] Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience
    Soomar, S. M.
    ANNALS OF ONCOLOGY, 2021, 32 : S777 - S777
  • [37] MYC gene rearrangement in diffuse large B-cell lymphoma does not confer a worse prognosis following dose-adjusted EPOCH-R
    Lai, Catherine
    Roschewski, Mark
    Melani, Christopher
    Pittaluga, Stefania
    Shovlin, Margaret
    Steinberg, Seth M.
    Dunleavy, Kieron
    Pack, Svetlana
    Jaffe, Elaine S.
    Wilson, Wyndham H.
    LEUKEMIA & LYMPHOMA, 2018, 59 (02) : 505 - 508
  • [38] Dose-adjusted EPOCH-R therapy in MYC-rearranged diffuse large B-cell lymphoma: not yet the standard of care reply
    Wilson, Wyndham H.
    LANCET HAEMATOLOGY, 2019, 6 (03): : E120 - E120
  • [39] Good Outcome after R-Hyper-CVAD/R-MA in High-Risk Aggressive B-Cell Lymphoma: A Single-Center Experience
    Sonnevi, Kristina
    Ljungqvist, Maria
    Joelsson, Joel K.
    Harrysson, Sara
    Wasterlid, Tove
    Bernell, Per
    Wahlin, Bjorn
    BLOOD, 2021, 138
  • [40] Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience.
    Devi, Kanta
    Shaikh, Muhammad Usman
    Ali, Natasha Bahadur
    Adil, Salman Naseem
    Khan, Maria
    Soomar, Salman Muhammad
    LEUKEMIA RESEARCH REPORTS, 2021, 16
12345